Since its initial description more than 50 years ago, SHORT syndrome is an acronym composed of the five main clinical characteristics encountered in the few patients reported in the medical literature so far [1] [2] [3] [4]:

• Short stature - Although up to one-third of cases present in the lower range of normal body height, short stature and a small height relative to the gestational age is a defining feature of this syndrome [5]. In addition to intrauterine growth retardation (IGR), which is readily noted, microcephaly, delayed bone age, and gracile long bones are observed in the majority of cases [5].
• Hyperextensibility of joints and/or hernias - Present only in a minority of individuals (around 35%).
• Ocular depression and Rieger anomaly - Dysgenesis of the anterior chamber, often described in the literature as the Rieger anomaly, is a cardinal feature and is seen in 100% of SHORT syndrome patients [1] [3] [4] [6].
• Tooth eruption delay - Similarly to ocular depression, delay in the eruption of teeth is confirmed in almost every patient suffering from SHORT syndrome [3] [4] [6].

In addition to the above mentioned signs and symptoms, several other features are described in this small group of individuals: facial anomalies (micrognathia, a triangular appearance of the face, megalocornea, anteverted ears, and hypoplasia of the nasal alae), lipodystrophy (near complete absence of subcutaneous fat), insulin resistance and eventual development of diabetes mellitus, hearing impairment, clinodactyly, and normal intellectual development, which may be particularly important in distinguishing SHORT syndrome from many other genetic diseases that affect mental development [1] [6] [7].

Given the rarity of the condition (only 20 cases described until the end of the 20th century), the diagnosis of SHORT syndrome is difficult. But because clinical suspicion can only be raised after a thorough physical examination and a properly obtained patient history, these two steps must be regarded as essential in order to make the diagnosis. Identification of the five cardinal features that constitute the SHORT acronym will almost undoubtedly confirm the diagnosis. On the other hand, several reports imply that an autosomal dominant pattern of inheritance is the mode of SHORT syndrome transmission, although many cases have developed following de novo mutations without any association suggesting a familial event [1] [2] [6]. Nevertheless, a comprehensive family history should be obtained. The cause of SHORT syndrome was unknown until recently, but the discovery of phosphatidylinositol 3 kinase (PI3K) mutations in practically all individuals has opened up the possibility of genetic testing in patients with the typical clinical features of SHORT [1] [3] [5]. These tests are scarcely available, however, which is why the diagnosis rests on clinical criteria. Mutations in BMP4 and the PITX family of genes have also been described in certain studies, but their roles are yet to be confirmed [5] [6].

There is no cure for SHORT syndrome, and treatment focuses on managing the symptoms and complications. Growth hormone therapy may be considered to address short stature, although its effectiveness can vary. Regular monitoring and management of insulin resistance or diabetes are crucial. Orthodontic treatment may be necessary for dental issues, and regular eye examinations are important to address any vision problems. A multidisciplinary approach involving endocrinologists, ophthalmologists, and other specialists is often beneficial.

The prognosis for individuals with SHORT syndrome varies depending on the severity of symptoms and the presence of complications. While the condition can present challenges, many individuals lead relatively normal lives with appropriate management. Early diagnosis and intervention can improve outcomes, particularly in managing growth and metabolic issues.

SHORT syndrome is primarily caused by mutations in the PIK3R1 gene, which is involved in the PI3K/AKT signaling pathway. This pathway is crucial for regulating cell growth, proliferation, and survival. Mutations in this gene disrupt normal cellular functions, leading to the various features of the syndrome. The condition is inherited in an autosomal dominant manner, meaning a single copy of the mutated gene can cause the disorder.

SHORT syndrome is extremely rare, with only a few dozen cases reported in the medical literature. Due to its rarity, the exact prevalence is unknown. The condition affects both males and females, and there is no known ethnic or geographical predilection.

The pathophysiology of SHORT syndrome involves disruptions in the PI3K/AKT signaling pathway due to mutations in the PIK3R1 gene. This pathway is essential for normal cellular functions, including growth and metabolism. The mutations lead to impaired signaling, resulting in the characteristic features of the syndrome, such as growth retardation, insulin resistance, and ocular abnormalities.

As SHORT syndrome is a genetic disorder, there are no known preventive measures. Genetic counseling may be beneficial for affected individuals and their families to understand the inheritance pattern and the risk of passing the condition to offspring. Prenatal genetic testing can be considered for families with a known history of the syndrome.

SHORT syndrome is a rare genetic disorder characterized by short stature, distinctive facial features, and other physical abnormalities. It is caused by mutations in the PIK3R1 gene, affecting the PI3K/AKT signaling pathway. Diagnosis involves clinical evaluation and genetic testing, while treatment focuses on managing symptoms. Although the condition presents challenges, individuals can lead fulfilling lives with appropriate care and management.

If you or a loved one has been diagnosed with SHORT syndrome, it's important to work closely with a team of healthcare professionals to manage the condition. Regular check-ups and monitoring can help address growth, metabolic, and vision issues. Genetic counseling can provide valuable information about the condition and its inheritance. Remember, while SHORT syndrome is rare, support and resources are available to help manage the condition effectively.

1. Dyment DA, Smith AC, Alcantara D, et al. Mutations in PIK3R1 Cause SHORT Syndrome. Am J Hum Genet. 2013;93(1):158-166.
2. Lipson AH, Cowell C, Gorlin RJ. The SHORT syndrome: further delineation and natural history. Journal of Medical Genetics. 1989;26(7):473-475.
3. Chudasama KK, Winnay J, Johansson S, et al. SHORT Syndrome with Partial Lipodystrophy Due to Impaired Phosphatidylinositol 3 Kinase Signaling. Am J Hum Genet. 2013;93(1):150-157.
4. Koenig R, Brendel L, Fuchs S. SHORT syndrome. Clin Dysmorphol. 2003;12(1):45-49.
5. Thauvin-Robinet C, Auclair M, Duplomb L, et al. PIK3R1 Mutations Cause Syndromic Insulin Resistance with Lipoatrophy. Am J Hum Genet. 2013;93(1):141-149.
6. Singh A, Arora R, Singh P, Kapoor S. Short syndrome-an expanding phenotype. Indian Pediatr. 2013;50(4):414-416.
7. Joo SH, Raygada M, Gibney S, Farzaneh I, Rennert OM. Case report on SHORT syndrome. Clin Dysmorphol. 1999;8(3):219-221.